Roche’s Spark Therapeutics, Bluebird Settle Trademark Suit (1)

Roche Holding AG’s Spark Therapeutics Inc. and rival Bluebird Bio Inc. settled a trademark infringement suit over Bluebird’s use of “spark” in a campaign for gene therapy treatments for sickle cell disease, according to a filing in federal court in Delaware.

No details of the settlement agreement were provided in the stipulation of dismissal filed Monday in the US District Court for the District of Delaware. Judge William C. Bryson hasn’t yet approved the pact.

Lawyers representing Spark declined to comment because the terms of the settlement are confidential. Lawyers for Bluebird didn’t immediately respond to requests for comment.

Spark ...